{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-23-020619","form_type":"8-K","ticker":null,"cik":"0001358403","company_name":"BELLICUM PHARMACEUTICALS, INC","filed_at":"2023-06-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.556389+00:00","generated_at":"2026-06-14T08:04:39.775682+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Bellicum Pharma terminates CEO Richard Fair and CDO Charity Scripture; effective June 30, 2023","bullets":["CEO Richard Fair and CDO Charity Scripture notified on May 31 that employment ends June 30, 2023.","Both receive severance per agreements; Scripture gets COBRA reimbursement for up to 12 months.","Both will sign consulting agreements to continue as officers as consultants on hourly basis.","Severance conditioned on providing a general release of claims for the company."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-23-020619","json":"https://secwatch.observer/filing/0001628280-23-020619.json","markdown":"https://secwatch.observer/filing/0001628280-23-020619.md","text":"https://secwatch.observer/filing/0001628280-23-020619.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1358403/000162828023020619/0001628280-23-020619-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1358403/000162828023020619/blcm-20230602.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T08:04:39.775682+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3e946a6f02","claim":"Richard Fair was terminated as President and Chief Executive Officer at BELLICUM PHARMACEUTICALS, INC.","evidence_excerpt":"On May 31, 2023, the Company provided notices to Richard Fair, President and Chief Executive Officer, and Charity Scripture, Chief Development Officer that their employment by the Company will terminate on June 30, 2023.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1358403/000162828023020619/0001628280-23-020619-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"terminated"},{"label":"Role","value":"President and Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"ad4102198f","claim":"Charity Scripture was terminated as Chief Development Officer at BELLICUM PHARMACEUTICALS, INC.","evidence_excerpt":"On May 31, 2023, the Company provided notices to Richard Fair, President and Chief Executive Officer, and Charity Scripture, Chief Development Officer that their employment by the Company will terminate on June 30, 2023.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1358403/000162828023020619/0001628280-23-020619-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"terminated"},{"label":"Role","value":"Chief Development Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}